Literature DB >> 22479042

Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.

Chiranjeev Sanyal1, Ethel Langille Ingram, Ingrid S Sketris, Kevork M Peltekian, Susan Kirkland.   

Abstract

BACKGROUND: The prevalence of infection with hepatitis C virus (HCV) is increasing worldwide. Antiviral therapy, prescription and nonprescription medications, and nondrug therapies to treat HCV infection and to manage associated adverse effects are costly.
OBJECTIVE: To determine whether individuals infected with HCV attending a hepatology clinic were negatively affected by the costs of prescription medications, and if so, to determine coping strategies they adopted.
METHODS: Patients infected with HCV attending Hepatology Services, a clinic within the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia, were interviewed as part of an exploratory study (April 2 to July 8, 2008). The interview was based on a validated survey adapted for Nova Scotia. Information collected included demographic characteristics; types of prescription, nonprescription, and complementary medications used by patients; and strategies patients adopted to pay their medication costs.
RESULTS: Fifty patients (age 33-64 years) participated in the interviewer-administered survey, including 35 (70%) men and 19 people (38%) with household income less than $30 000. Frequently used medications were antidepressants (19 patients [38%]), antihypertensive agents (12 [24%]), anxiolytics (10 [20%]), and nonsteroidal anti-inflammatory drugs (10 [20%]). More than half (29 [58%]) were concerned about having sufficient money to pay for their medications. Coping strategies adopted in response to costs of prescription medications were either self-initiated or undertaken in consultation with physicians and/or other health care professionals. Sixteen (32%) of the respondents expressed the belief that physicians usually do not consider patients' concerns about affordability when prescribing medications. Seven (14%) indicated they would seek help from a pharmacist to buy low-cost substitutes for their medications.
CONCLUSION: This study highlighted a range of coping strategies adopted by patients infected with HCV in response to medication costs. It underscores that cost may limit access to essential medications within this patient population, even in a publicly funded health care system. Some of the coping strategies adopted might reduce patients' persistence and adherence with medication therapy, which could lead to adverse health outcomes. Hospital and community pharmacists need to be aware of the challenges faced by patients in terms of paying for medications and should consider possible proactive responses to address potentially detrimental coping strategies.

Entities:  

Year:  2011        PMID: 22479042      PMCID: PMC3093420          DOI: 10.4212/cjhp.v64i2.997

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  39 in total

1.  Blurring of the public/private divide: the Canadian chapter.

Authors:  Colleen M Flood; Bryan Thomas
Journal:  Eur J Health Law       Date:  2010-06

2.  Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

Authors:  Vincenzo Atella; Ellen Schafheutle; Peter Noyce; Karen Hassell
Journal:  Appl Health Econ Health Policy       Date:  2005       Impact factor: 2.561

3.  When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions.

Authors:  Aslam H Anis; Daphne P Guh; Diane Lacaille; Carlo A Marra; Amir A Rashidi; Xin Li; John M Esdaile
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

Review 4.  Hepatitis C: diagnosis and treatment.

Authors:  Thad Wilkins; Jennifer K Malcolm; Dimple Raina; Robert R Schade
Journal:  Am Fam Physician       Date:  2010-06-01       Impact factor: 3.292

5.  Physician strategies to reduce patients' out-of-pocket prescription costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; David O Meltzer
Journal:  Arch Intern Med       Date:  2005-03-28

Review 6.  A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures.

Authors:  John D Piette; Michele Heisler; Robert Horne; G Caleb Alexander
Journal:  Soc Sci Med       Date:  2005-08-10       Impact factor: 4.634

7.  Access to medicines: cost as an influence on the views and behaviour of patients.

Authors:  Ellen I Schafheutle; Karen Hassell; Peter R Noyce; Marjorie C Weiss
Journal:  Health Soc Care Community       Date:  2002-05

8.  Barriers to patient-physician communication about out-of-pocket costs.

Authors:  G Caleb Alexander; Lawrence P Casalino; Chien-Wen Tseng; Diane McFadden; David O Meltzer
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

Review 9.  Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Clin Liver Dis       Date:  2003-02       Impact factor: 6.126

10.  Physician consideration of patients' out-of-pocket costs in making common clinical decisions.

Authors:  Hoangmai H Pham; G Caleb Alexander; Ann S O'Malley
Journal:  Arch Intern Med       Date:  2007-04-09
View more
  4 in total

Review 1.  Protease inhibitors for hepatitis C: economic implications.

Authors:  Stuart J Turner; Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

2.  Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review.

Authors:  Amirhossein Modabbernia; Hossein Poustchi; Reza Malekzadeh
Journal:  Hepat Mon       Date:  2013-01-07       Impact factor: 0.660

3.  Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.

Authors:  Mohamed A Daw; Aghynya A Dau; Mohamed M Agnan
Journal:  ScientificWorldJournal       Date:  2012-12-27

Review 4.  Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.

Authors:  Caroline O'Keefe-Markman; Kristina Dawn Lea; Christopher McCabe; Elaine Hyshka; Tania Bubela
Journal:  BMC Public Health       Date:  2020-01-20       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.